Corrigendum to "No evidence for prolonged excretion of polioviruses in persons with residual paralytic poliomyelitis in Ethiopia, Pakistan and Guatemala" [Biologicals 34 (2006) 113-116] (DOI:10.1016/j.biologicals.2006.03.004);No evidence for prolonged excretion of polioviruses in persons with residual paralytic poliomyelitis in Ethiopia, Pakistan and Guatemala

Biologicals

Volumn 34, Issue 2, 2006, Pages 113-116

  Khan, Aamir J ^a   Gebreselassie, Hailemichael ^b   Asturias, Edwin J ^a   Agboatwalla, Mubina ^c   Teklehaimanot, Redda ^d   Luby, Stephen P ^e   Bayene, Berhane ^b   Chezzi, Claudia ^f   Asghar, Humayun ^g   Moatter, Tariq ^e   Torres, Olga R ^h   Kew, Olen ⁱ   Winkelstein, Jerry ^j   Halsey, Neal A ^a,j  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b ETHIOPIAN PUBLIC HEALTH INSTITUTE   (Ethiopia)

^c CIVIL HOSPITAL   (Pakistan)

^d Grarbet Ledekuman Rehabilitation Center   (Ethiopia)

^e AGA KHAN UNIVERSITY   (Pakistan)

^f National Institute of Virology   (South Africa)

^g NATIONAL INSTITUTE OF HEALTH   (Pakistan)

^h Institute of Nutrition of Central America and Panama Guatemala   (Guatemala)

ⁱ CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

B cell immunodeficiency; Developing country settings; IgG IgA deficiencies; Paralytic poliomyelitis; Poliovirus excretion; Poliovirus gene sequencing

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; ETHIOPIA; FEMALE; GUATEMALA; HUMAN; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN G DEFICIENCY; INDUSTRIALIZATION; MAJOR CLINICAL STUDY; MALE; PAKISTAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; SCREENING; VIRUS EXCRETION;

POLIOVIRUS;

EID: 33646883494     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2007.01.001     Document Type: Erratum

References (21)

1. Sutter R.W., Cochi S.L., and Melnick J.L. Live attenuated poliovirus vaccines. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 3rd ed. (1999), WB Saunders Co, Philadelphia 364-408
2. Modlin J.F. Coxsackieviruses, echoviruses, and newer enteroviruses. In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 5th ed. (2000), Churchill-Livingstone, Philadelphia, Pa 1904-1919
3. Wood D.J., Sutter R.W., and Dowdle W.R. Stopping poliovirus vaccination after eradication: issues and challenges. Bull World Health Organ 78 3 (2000) 347-357
4. Heymann D.L. Polio eradication: finishing the job and protecting the investment. Bull World Health Organ 82 1 (2004) 1
5. Aylward R.B., and Cochi S.L. Framework for evaluating the risks of paralytic poliomyelitis after global interruption of wild poliovirus transmission. Bull World Health Organ 82 1 (2004) 40-46
6. Fine P.E.M., Oblapenko G., and Sutter R.W. Polio control after certification: major issues outstanding. Bull World Health Organ 82 1 (2004) 47-52
7. Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., and Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 59 (2005) 587-635
8. Sutter R.W., and Prevots D.R. Vaccine-associated paralytic poliomyelitis among immunologically abnormal persons. Infect Med 11 (1994) 429-430
9. Khetsuriani N., Prevots D.R., Quick L., Elder M.E., Pallansch M., Kew O., et al. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J Infect Dis 188 (2003) 1845-1852
10. WHO field guide for supplementary activities aimed at achieving polio eradication. Form 3e Laboratory Request Form; 1995.
11. Kew O.M., Mulders M.N., Lipskaya G.Y., da Silva E.E., and Pallansch M.A. Molecular epidemiology of polioviruses. Semin Virol 6 (1995) 401-414
12. Ochs H.D., Smith C.I.E., and Puck J.M. Primary immunodeficiency diseases: a molecular and genetic approach (1999), Oxford University Press, New York p. 250-58
13. Kew O.M., Wright P.F., Agol V.I., Delpeyroux F., Shimizu H., Nathanson N., et al. Circulating vaccine-derived polioviruses: current state of knowledge. Bull World Health Organ 82 (2004) 6-23
14. Cherkasova E.A., Yakovenko M.L., Rezapkin G.V., Korotkova E.A., Ivanova O.E., Eremeeva T.P., et al. Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine. J Virol 79 (2005) 1062-1070
15. Halsey N.A., Pinto J., Espinosa-Rosales F., Faure-Fontenla M.A., da Silva E., Khan A.J., et al. Search for poliovirus carriers among people with primary immune deficiency disease in the United Status, Mexico, Brazil, and the United Kingdom. Bull World Health Organ 82 (2004) 3-8
16. Pavlov D.N., Van Zyl W.B., Van Heerden J., Grabow W.O., and Ehlers M.M. Prevalence of vaccine-derived polioviruses in sewage and river water in South Africa. Water Res 39 (2005) 3309-3319
17. Tharmaphornpilas P. Vaccine-derived poliovirus, Thailand, 2003. Emerg Infect Dis 11 (2005) 777-778
18. Sutter R.W., Caceres V.M., and Lago P.M. The role of routine polio immunization in the post-certification era. Bull World Health Organ 82 (2004) 31-39
19. John T.J. A developing country perspective on vaccine-associated paralytic poliomyelitis. Bull World Health Organ 82 (2004) 53-57
20. Aylward R.B., Sutter R.W., and Heymann D.L. Policy. OPV cessation - the final step to a "polio-free" world. Science 310 (2005) 625-626
21. World Health Organization. Conclusions and recommendations. WHO informal consultation on identification and management of vaccine-derived polioviruses (2003), World Health Organization, Geneva